

iDose® TR (travoprost intracameral implant)

When requesting iDose® TR (travoprost intracameral implant), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

iDose TR is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Coverage Guidelines

Reduction of intraocular pressure (IOP) with open-angle glaucoma (OAG) or ocular hypertension (OHT)

The individual must meet all of the following criteria for authorization:

- Is 18 years of age or older;
- Is not receiving re-treatment of eye(s) previously treated with iDose TR;
- Has experienced inadequate efficacy or severe adverse event(s) to at least two ophthalmic prostaglandins (as monotherapy or concomitant therapy) for the treatment of open-angle glaucoma or ocular hypertension (e.g., bimatoprost ophthalmic solution, latanoprost ophthalmic solution, travoprost ophthalmic solution, latanoprostene bunod ophthalmic solution, tafluprost ophthalmic solution, omidenepag isopropyl ophthalmic solution);
- Has experienced inadequate efficacy or severe adverse event(s) to at least two ophthalmic products (as monotherapy or concomitant therapy) from two different pharmacological classes for the treatment of open-angle glaucoma or ocular hypertension (e.g., beta-blockers, alpha-agonist [brimonidine], carbonic anhydrase inhibitors, rho kinase inhibitor [netarsudil]);
- iDose TR is administered by or under the supervision of an ophthalmologist.

Approval duration: one time use in each treated eye (a total of two implants)

Dosing Recommendation

For ophthalmic intracameral administration only.

The recommended dose is one iDose TR implant per treated eye, a total of two implants per patient.

References

1. iDose® TR intracameral implant [prescribing information]. San Clemente, CA: Glaukos; December 2023
2. Boyd K. Glaucoma. Available at: <https://www.aao.org/eye-health/diseases/what-is-glaucoma>. Last reviewed, December 4, 2023. Accessed on February 14, 2024.
3. Gedde SJ, Vinod K, Wright MW, et al. Primary open-angle glaucoma Preferred Practice Pattern® guidelines. The American Academy of Ophthalmology. 2020. Available at: <https://www.aao.org/education/preferred-practice-pattern/primary-open-angle-glaucoma-ppp>. Accessed on February 14, 2024.
4. Facts and Comparisons® Online. Wolters Kluwer Health, Inc.; 2024. Available at: <https://fco.factsandcomparisons.com/lco/action/home>. Accessed on February 14, 2024. Search terms: ophthalmic beta blockers, alpha agonists, prostaglandins, netarsudil.
5. Sarkisian SR, Ang RE, Lee AM, Berdahl JP, Heersink SB, Burden JH, Doan LV, Stephens KG, Applegate D, Kothe AC, Usner DW, Katz LJ, Navratil T. Travoprost Intracameral Implant for Open-Angle Glaucoma or Ocular Hypertension: 12-Month Results of a Randomized, Double-Masked Trial. Ophthalmol Ther. 2024 Apr;13(4):995-1014. doi: 10.1007/s40123-024-00898-y. **Trial registration:** ClinicalTrials.gov identifier, [NCT03519386](https://clinicaltrials.gov/ct2/show/study/NCT03519386).